The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis

Abstract

Abstract The 21-gene recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit in early estrogen receptor-positive (ER +) HER2-negative (HER2-) breast cancer (BCA). We evaluated clinicopathologic characteristics, RS and chemotherapy benefit in invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and carcinomas of mixed histologies (ductal + lobular (DLC), ductal + other (DOC), lobular + other (LOC)). Women diagnosed between 1/1/2010 and 1/1/2014 with ER + HER2- BCA, measuring 26. ILC was associated with larger size, and least likely to be high grade (p 26. IDC patients (pts) were more likely to receive chemotherapy than pts with other histologies (p 26 cannot be excluded.